Gossamer Bio Competitors
| GOSS Stock | USD 0.37 -0.01 -2.63% |
Correlation: Gossamer Bio vs Regenxbio View
Poor diversification
Gossamer Bio currently posts a 0.79 correlation with Regenxbio, indicating a Poor diversification relationship for the active sample. In portfolio terms, the overlap shows how much shared movement remains after combining both positions.
Moving together with Gossamer Stock
Moving Against Gossamer Stock
The mean reversion principle applied to Gossamer Bio's suggests that neither prolonged outperformance nor underperformance is permanent. Identifying the root cause of Gossamer Bio's price dislocation is essential before acting on a mean reversion signal.
Gossamer Bio Competition Correlation Matrix
Reviewing how Gossamer Bio moves relative to competing stocks can show whether peer exposure is reducing portfolio risk or simply repeating the same market bet. This matrix is most informative when investors want to know whether adding another peer would improve diversification, increase crowding, or leave total risk largely unchanged.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
Strong recent returns in Gossamer Stock do not always mean Gossamer Bio Company is outperforming peers on business quality. Peer-relative risk metrics add context on drawdown behavior, consistency, and return quality. These indicators are quantitative in nature and help investors evaluate volatility and risk-adjusted expected returns across different positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| KALV | 2.88 | 0.43 | 0.13 | 0.66 | 3.12 | 6.19 | 15.04 | |||
| FDMT | 3.21 | 0.39 | 0.09 | 0.42 | 4.08 | 7.32 | 24.58 | |||
| OLMA | 3.26 | -1.05 | 0.00 | 15.90 | 0.00 | 6.25 | 35.57 | |||
| VTYX | 2.92 | 0.73 | 0.20 | -0.99 | 2.74 | 9.00 | 37.04 | |||
| LXRX | 3.87 | 0.75 | 0.13 | 0.48 | 4.73 | 9.17 | 38.53 | |||
| RIGL | 2.40 | -0.57 | 0.00 | -0.68 | 0.00 | 3.58 | 18.93 | |||
| PRTA | 2.13 | 0.18 | 0.07 | 0.06 | 2.30 | 6.64 | 12.98 | |||
| CRVS | 6.76 | 1.76 | 0.45 | -0.48 | 3.86 | 8.14 | 175.94 | |||
| RAPT | 3.28 | 1.21 | 0.33 | 3.71 | 2.33 | 7.76 | 64.19 | |||
| RGNX | 4.06 | -0.62 | 0.00 | 0.73 | 0.00 | 7.48 | 26.35 |
Peer Comparison: Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Gossamer Bio financial statement analysis. It represents the amount of money remaining after all of Gossamer Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Compare Gossamer Bio and related stocks such as Kalvista Pharmaceuticals, 4D Molecular Therapeutics, and Olema Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KALV | -2.1 M | -2.1 M | -2.1 M | -5.7 M | -13.4 M | -24.8 M | -18.6 M | -15.8 M | -20.8 M | -29.1 M | -46.2 M | -82.3 M | -92.9 M | -126.6 M | -183.4 M | -24.8 M | -26.1 M |
| FDMT | -11.2 M | -11.2 M | -11.2 M | -11.2 M | -11.2 M | -11.2 M | -11.2 M | -11.2 M | -9.6 M | -49.3 M | -56.7 M | -68.3 M | -101.1 M | -100.8 M | -160.9 M | -140.1 M | -133.1 M |
| OLMA | -2.2 M | -2.2 M | -2.2 M | -2.2 M | -2.2 M | -2.2 M | -2.2 M | -2.2 M | -2.2 M | -4.3 M | -22.1 M | -71.1 M | -102.6 M | -96.7 M | -129.5 M | -162.5 M | -154.3 M |
| VTYX | -4.5 M | -4.5 M | -4.5 M | -4.5 M | -4.5 M | -4.5 M | -4.5 M | -4.5 M | -4.5 M | -4.5 M | -28.2 M | -83.7 M | -108.4 M | -193 M | -135.1 M | -121.6 M | -127.7 M |
| LXRX | -12.5 M | -116.2 M | -110.2 M | -104.1 M | -100.3 M | -4.7 M | -141.4 M | -129.1 M | -120.5 M | 130.1 M | -58.6 M | -87.8 M | -101.9 M | -177.1 M | -200.4 M | -50.3 M | -52.9 M |
| RIGL | -12.4 M | -86 M | -98.8 M | -89 M | -90.9 M | -51.5 M | -69.2 M | -78 M | -70.5 M | -66.5 M | -29.7 M | -17.9 M | -58.6 M | -25.1 M | 17.5 M | 367 M | 385.4 M |
| PRTA | -12.5 M | -29.7 M | -41.4 M | -41 M | -7.2 M | -80.6 M | -160.1 M | -153.2 M | -155.6 M | -77.7 M | -111.1 M | 67 M | -116.9 M | -147 M | -122.3 M | -244.1 M | -231.9 M |
| CRVS | -176 K | -176 K | -176 K | -176 K | -176 K | -31.3 M | -36.4 M | -55.7 M | -46.9 M | -43.7 M | -4.8 M | -43.2 M | -41.3 M | -27 M | -62.3 M | -15.3 M | -16 M |
| RAPT | -29.1 M | -29.1 M | -29.1 M | -29.1 M | -29.1 M | -29.1 M | -29.1 M | -29.1 M | -36.1 M | -43 M | -52.9 M | -68.2 M | -81.9 M | -116.8 M | -129.9 M | -116.9 M | -111 M |
| RGNX | -5.4 M | -5.4 M | -5.4 M | -5.4 M | -4 M | -22.8 M | -63 M | -73.2 M | 99.9 M | -94.7 M | -111.2 M | 127.8 M | -280.3 M | -263.5 M | -227.1 M | -193.9 M | -184.2 M |
Gossamer Bio Competitive Analysis
How does Gossamer Bio measure up against Kalvista Pharmaceuticals, 4D Molecular, and Olema Pharmaceuticals? The financials tell a nuanced story. Gossamer Bio operates at a 88.0 M scale with 48.5 M flowing through the income statement. Gossamer Bio posts a -783.37% return on equity, reflecting current earnings headwinds. Market capitalization diverges sharply here: 832.0 M versus 88.0 M, giving Kalvista Pharmaceuticals a clear size advantage. On equity returns, 4D Molecular earns -27.57% compared to -783.37% at Gossamer Bio. Return on equity favors Olema Pharmaceuticals at -36.61%, well ahead of Gossamer Bio at -783.37%.| Better Than Average | Worse Than Peers | View Performance Chart |
Gossamer Bio Competition Peer Performance Charts
How to Analyze Gossamer Bio Against Peers
Gossamer Bio's peer analysis compares Gossamer Bio with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Gossamer Bio trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Gossamer Bio leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Revenue at Gossamer Bio has grown faster than the peer median over the last four quarters, widening its competitive lead. The peer set can help frame whether recent outperformance is broad-based or company-specific. For peer comparison, Gossamer Bio has a market cap of 87.96 M.
For Gossamer Bio, this section uses periodic company reporting and market reference feeds and standardizes the results for cross-period comparison. Intraday timing differences may exist.